Impressive Novartis has a habit of exceeding expectations
05/12/25 -"Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, neuroscience, immunology and CVRM (cardiovascular, renal ..."
Pages
63
Language
English
Published on
05/12/25
You may also be interested by these reports :
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...